AnalystBook Research · Company Intelligence

Ocugen, Inc.

OCGNNasdaq

Built from Ocugen, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Revenue increased 8.8% to $4.4M, while Net income decreased 25.5% to ($67.8M).

The read at a glance✓ Audited against SEC data
  • Scale — FY2025 revenue $4.4MWatch
  • Profitability — Net income ($67.8M)Watch
  • Cash generation — Free cash flow ($57.1M)Note
  • Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
  • Insiders — 0 buys; 0 sells in 365 daysNote
  • Capital — Comparable payout data unavailableNote

Business

Ocugen, Inc.: Our First-in-class, breakthrough modifier gene therapy platform presents a potential paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe.

Where the revenue comes from

Fiscal 2025, as Ocugen, Inc. reports it. History and quarterly detail are in the app.

  • Reportable$4.4M

Leadership changes

From Ocugen, Inc.'s own filings, the day they're filed.

  • Ramesh Ramachandran · Chief Accounting Officer · departureeff. 2026-05-29
  • Rita Johnson-Greene · Chief Financial Officer · appointmenteff. 2026-02-09
  • Marna C. Whittington · director · departureeff. 2025-04-21

Latest filings

  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-08-06
  • DEF 14A · Annual proxy (pay & governance)2026-07-30
  • 8-K · Company announcement2026-07-13
  • 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Ocugen, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full OCGN record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.